Bio-Rad Laboratories has launched two Epstein Barr Virus (EBV) kits for use on its BioPlex 2200 system, a diagnostic platform that employs multiplexing technology to s for multiple disease markers
Bio-Rad's BioPlex 2200 system is a diagnostic platform that employs multiplexing technology to analyse for multiple disease markers from a single patient sample.
"We are extremely pleased to offer our customers two new kits for EBV, including the only heterophile IgM assay available on an automated platform," said John Goetz, vice president of Bio-Rad's clinical diagnostics group.
"The release of the BioPlex 2200 EBV IgG and IgM kits is another example of Bio-Rad's commitment to providing valuable tools that provide laboratories ways to improve testing methods, maximize efficiencies, and lower costs".
Each of the two kits provides for multiple results from a single patient sample.
The IgG kit includes assays for EBV VCA, EBV NA-1, and EBV EA-D, and the IgM kit includes assays for EBV VCA and heterophile antibodies.
By delivering results for five of the most clinically relevant antibodies, the BioPlex 2200 system enables laboratories to rapidly determine patient serological status on a fully automated and fully integrated random access platform.
